Davison Steven P, Baglien Brigit D, Hayes Kylie D
DAVinci Plastic Surgery, Washington D.C.; Department of Plastic Surgery, Georgetown University School of Medicine, Washington D.C.; University of Maryland School of Medicine, Baltimore, Md.; and University of Arkansas School of Medical Sciences College of Medicine, Little Rock, Ark.
Plast Reconstr Surg Glob Open. 2017 Mar 28;5(3):e1282. doi: 10.1097/GOX.0000000000001282. eCollection 2017 Mar.
Psychoactive drug use is on the rise in the United States, with plastic surgery patients a potentially susceptible group. This study aimed to determine the incidence of cosmetic and reconstructive patients in our practice taking psychoactive drugs and to compare those values with the national average. Furthermore, we discuss the patient safety concerns when patients withhold their medical history information over the course of their treatment.
Urban private plastic practice patients who underwent surgery in a closed practice from 2009 to 2016 were divided into cosmetic and reconstructive cohorts. Review for drug use was medical scripts, history, and Surescripts drug reporting. Extracted information includes age, race, procedure, psychoactive medications, and whether or not they stated a mental health diagnosis on their medical history forms. Only patients with complete records were included.
A total of 830 patients were included in statistical analysis. Due to minimal cohort number, 70 men were excluded, as there were no comparative national data. Our analysis found that 33.6% cosmetic patients and 46.3% reconstructive patients used at least one psychoactive drug.
There is a statistically significant difference between psychoactive drug use at our practice compared with the general population and a significantly larger percentage of reconstructive patients taking drugs compared with the cosmetic cohort.
在美国,精神活性药物的使用呈上升趋势,整形手术患者是一个潜在的易感群体。本研究旨在确定我们诊所中接受整形和重建手术的患者使用精神活性药物的发生率,并将这些数值与全国平均水平进行比较。此外,我们还讨论了患者在治疗过程中隐瞒病史信息时的患者安全问题。
将2009年至2016年在一家封闭式诊所接受手术的城市私立整形诊所患者分为美容和重建两组。通过医疗处方、病史和Surescripts药物报告来审查药物使用情况。提取的信息包括年龄、种族、手术、精神活性药物,以及他们是否在病史表格上注明了心理健康诊断。仅纳入记录完整的患者。
共有830名患者纳入统计分析。由于队列数量极少,排除了70名男性,因为没有可比较的全国数据。我们的分析发现,33.6%的美容患者和46.3%的重建患者使用了至少一种精神活性药物。
与普通人群相比,我们诊所精神活性药物的使用存在统计学上的显著差异,与美容组相比,重建患者服用药物的比例明显更高。